Page 7 - Pharmaceutical

Corporate India gears up to hedge China supply risk amid Covid surge

The sectors in India that import from China include pharmaceutical (pharma), automotive (auto), textile, engineering, and electronic goods

Domestic, semi-regulated markets to drive pharmaceutical industry's growth

High raw material prices to put pressure on margins

Advent International to pick up 50.1% in Suven Pharma for Rs 6,313 crore

To launch open offer for another 26%; plans merger with Cohance

Alembic Pharma gets USFDA nod for generic drug to treat breast cancer

Alembic Pharmaceuticals on Monday said it has received final approval from the US health regulator for its generic Fulvestrant injection used in treatment of breast cancer. The approval granted by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA), Fulvestrant injection of strength 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, the company said in a statement. The approved injection is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, of AstraZeneca Pharmaceuticals LP, it added. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of breast cancer, the company said. For 12 months ended September 2022, Fulvestrant injection, 250 mg/5 mL, had an estimated market size of USD 71 million, the company said citing IQVIA data.

Maiden Pharma's cough syrups are safe, WHO jumped the gun: DCGI

'Irreparable damage' to Indian pharma's global image, drug regulator writes to WHO

Rising cost of raw materials a challenge for drug firms: Cipla's Hamied

Companies will have to manage work to match India's National List of Essential Medicines but it will be worth the endeavour, she says

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Drug trials on human tissues, cells made in labs soon; new rules in offing

Pre-clinical trials of new drugs could soon be done on human tissues and cells developed in laboratories and not just on animals as the Union Health Ministry is working on bringing in amendments to the New Drugs and Clinical Trials Rules, 2019. A recent draft notification to amend the rules stated that alternative technology platforms such as human organ on chips, micro-physiological systems and other in vitro or cell-based assays can be used prior to and in conjunction with animal testing to establish the safety and efficacy of new drugs before human clinical trials. Pre-clinical tests are important for establishing the safety and efficacy of investigational drugs. In September, the US Congress approved a landmark FDA Modernization Bill that allows a pharmaceutical drug developer to use alternative methods -- including cell-based assays, organ on chips, micro-physiological systems and other human biology-based test methods -- for establishing the safety and effectiveness of new or

Pharma logs 17% growth in Nov; anti-infective therapy drives market demand

Key antibiotic brands like Augmentin (GSK) and Clavam (Alkem) clocked 25 per cent and 29 percent growth, respectively, in November, the data showed

Innovator drugs maintain market hold even after patent expiry, shows data

Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms

Viatris deal gives Biocon Biologics entry in 100 countries: Shreehas Tambe

In a Q&A, the recently named MD & CEO of Biocon Biologics dwells on the scope for an IPO or stake sale to PE investors to retire the debt taken to fund the acquisition

Gland Pharma to acquire French firm Cenexi Group for Rs 1,000 crore

Will fund transaction from internal accruals

Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

China-Plus-One strategy: Indian API firms start to reap benefits

Rising Chinese labour costs, geopolitics, pandemic-stricken uncertainties have forced global players to derisk

Akums chalks out expansion plan as it eyes Rs 10,000 cr turnover by 2028

Leading contract manufacturing drug firm Akums Drugs & Pharmaceuticals plans to expand its presence globally and enhance product range as it looks to more than double its turnover to Rs 10,000 crore by 2028, as per the company's Joint Managing Director Sandeep Jain. The company, which produces around 12 per cent of all the medicines consumed in the country from its 15 manufacturing facilities, has a topline of about Rs 4,000 crore currently. In an interaction with PTI, Jain said the company would be able to achieve its stated financial targets even if it continues to grow at the same pace it has been doing over the last few years. He noted that the demand for pharmaceutical products is going to stay robust in the domestic market, with some estimates pointing towards the market doubling by 2030. "We expect to touch a turnover of Rs 10,000 crore in the next five years (2028)from the current level of Rs 4,000 crore. Our plan is to keep growing by at least 12-15 (CAGR)," Jain ...

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Top 300 drug brands to now have QR codes on label for ensuring authenticity

Govt finalises the draft notification issued in June

After the Gambia, Nigeria, Liberia issue alerts over Maiden Pharma's syrups

Nigeria has reportedly circulated the alert across all professional bodies, health care providers and supply chain associates

New Jersey-based Amneal Pharma starts mfg operations for Indian market

The firm already has manufacturing units in four Indian cities, all of which are focused on the export market

Can Roche stay ahead of the competition in the next 125 years?

Pharma giant Roche believes, its ability to reinvent itself through innovation was behind its success. Business Standard's Sohini Das and Nivedita Mookerji spoke to the members of its founding family